MT-RNR1 Genotype

Some people lose their hearing permanently after a single ordinary dose of gentamicin. Not a high dose, not a long course, not a monitoring failure. One dose, at a level that thousands of other people receive without any problem at all. The difference is usually a single letter of mitochondrial DNA.

That letter is in MT-RNR1 (the mitochondrially encoded 12S ribosomal RNA gene). This test reads it. If you carry one of the known risk variants, the result's whole value is the note it puts in your chart, the one that keeps a clinician from reaching for that antibiotic class in the first place.

What This Gene Actually Does

Every cell in your body runs on mitochondria, the small compartments that generate energy. They carry their own separate loop of DNA, and MT-RNR1 sits on it. The gene makes a piece of RNA that forms part of the mitochondrial ribosome, the machine that builds proteins inside those compartments.

Mitochondria descend from ancient bacteria, and their ribosomes still look a little bacterial. That resemblance is the whole problem. Aminoglycoside antibiotics work by jamming bacterial ribosomes. Certain MT-RNR1 variants, above all m.1555A>G, shift the shape of your mitochondrial ribosome so it looks even more bacterial than it should. The drug binds where it was never meant to bind.

The hair cells of the inner ear are unusually dependent on mitochondrial energy production and they do not regenerate. When they go, they stay gone. That's why the damage is permanent and why the test matters before exposure rather than after.

Aminoglycoside-Induced Hearing Loss

This is the association the test exists for, and it's the strongest one in the whole MT-RNR1 literature. A systematic review of the genetics behind hearing damage from these drugs found two variants, m.1555A>G and m.1494C>T, strongly linked to permanent inner-ear hearing loss after exposure.

The drugs in question are gentamicin, tobramycin, amikacin, and streptomycin. They're mainstays in neonatal intensive care, in serious hospital infections, and in cystic fibrosis, where people receive repeated courses for years.

Among Chinese pediatric patients with hearing loss, mutations in the mitochondrial 12S rRNA gene accounted for about 30% of aminoglycoside-induced deafness cases. In a study of people carrying m.1555A>G, the loss hit both ears about equally, was worst at high frequencies, and got worse with streptomycin. Balance was unaffected, which is part of why the problem goes unnoticed until it has already happened.

The practical consequence is simple. Knowing your genotype changes which antibiotic you get. In the cystic fibrosis population, where large-scale screening has been studied, identifying a carrier means choosing a different drug that treats the infection just as well without putting your hearing at risk.

Why the Damage Is Invisible Until It Isn't

The most useful finding for anyone considering this test comes from newborn screening. Among 11,509 neonates carrying common deafness-associated variants, every infant with m.1555A>G or m.1494C>T passed the standard newborn hearing screen.

Read that again. The physiological hearing test, the one every newborn in most countries gets, correctly recorded normal hearing in all of them. It was correct. Their hearing was normal at that moment. What it could not see was that their hearing would not survive a course of gentamicin.

That's the gap this test fills. A hearing test measures hearing you have today. A genotype tells you what your hearing can tolerate. In a pilot study of 8,261 newborns, adding targeted genomic sequencing to routine screening flagged an extra 1.5% of children at risk for inner-ear hearing loss.

What Carrying a Variant Does Not Mean

Carrying a risk variant is not the same as being destined for deafness, and the evidence here cuts against the alarmist reading. Some people carry m.1555A>G in every copy of their mitochondrial DNA and keep completely normal hearing their whole lives, as long as they never meet the drug. Others develop progressive hearing loss on their own. The range runs from normal hearing to profound deafness even without exposure.

What seems to decide the outcome is how much of the drug you take over a lifetime and what fraction of your mitochondria carry the variant. The rest of your mitochondrial DNA matters too. Among Eastern Asian families carrying m.1555A>G, one maternal lineage (haplogroup B) raised the risk of hearing loss while two others, D and M8, lowered it.

So the two findings that look contradictory, a variant strongly tied to devastating drug-induced deafness and carriers walking around with perfect hearing, fit together cleanly. This is a marker of intolerance to a specific exposure rather than a marker of disease. The variant sets the vulnerability; the drug decides whether the vulnerability ever becomes an event.

Not All MT-RNR1 Variants Behave the Same

m.1555A>G and m.1494C>T carry the clearest evidence. Other variants in the gene do different things, or in some cases we don't yet know what they do.

In a Taiwanese adult population of 59,091 people, the m.827A>G variant was associated with hearing loss, but its role in gentamicin-related hearing damage appeared limited. Same gene, different variant, different clinical meaning. Another variant, G709A, was tied to shorter survival and earlier spread in people being treated for liver cancer, most strongly in those 65 and under. That says something about the course of a cancer someone already has. It says nothing about who will get one, and it is no reason to test for liver cancer risk.

Then there are the ones nobody can interpret yet. In unselected clinical sequencing samples, a sizeable minority carry an MT-RNR1 variant that has been linked to hearing loss at some point in the literature, and most of those have no established meaning. If your report names something other than m.1555A>G or m.1494C>T, that is usually the category you're in.

What Your Result Means for Your Relatives

Mitochondrial DNA comes entirely from your mother. Nothing from your father, nothing recombined. That makes the family picture unusually clean.

If the variant sits in all of your mitochondrial DNA, your mother almost certainly carries it, your siblings almost certainly carry it, and if you're a woman, all of your children will carry it. Sons carry it but do not pass it on. One positive result maps a whole maternal line at once, which is why testing along that line is worth doing rather than testing one person at a time.

This is also the single biggest reason to test before a pregnancy rather than after a hospital admission. A woman who knows she carries the variant knows her newborn carries it, and that knowledge is in the chart before anyone in a neonatal unit reaches for gentamicin at 3 a.m.

A One-Time Test, Then a Lifetime of Use

Your genotype doesn't change. Sequence it once and you never sequence it again. What matters is whether the result is somewhere a clinician will actually see it when the decision arises, which is usually during an urgent admission when nobody is reading your old lab folder.

So there's no retesting to do. The follow-up work is three things: get the result onto your medication allergy and alert list, not buried in a genetics report; carry it with you in a form you can show in an emergency department; and tell your maternal relatives so they can decide whether to test.

If you carry a variant and receive an aminoglycoside anyway, because sometimes there is no alternative for a life-threatening infection, then hearing needs tracking. Pure-tone audiometry and otoacoustic emissions testing record where your hearing started and catch any drop afterward. Get a baseline before any planned exposure if you can.

What an Unexpected Result Should Make You Do

A positive result for m.1555A>G or m.1494C>T is actionable on its own and doesn't need a second opinion to be useful. Put it on your drug alert list, notify your maternal relatives, and if you have cystic fibrosis, bronchiectasis, or any condition that brings repeated courses of intravenous or inhaled antibiotics, raise it with the team managing those infections before the next course rather than during it.

A result naming an unfamiliar variant is a different situation. Sorting a rare variant that actually matters from one of the many uncertain ones means weighing the exact position, how much of your mitochondrial DNA carries it, and your ancestry together, which is work for a clinical geneticist. Bring the family history with you, specifically whether anyone on your mother's side has unexplained hearing loss or lost hearing after a hospital stay.

If you already have unexplained hearing loss and this test comes back negative, the workup isn't over. Most inherited hearing loss comes from nuclear genes rather than mitochondrial ones. Changes in one gene, GJB2, account for a large share of deafness that is present at birth without other medical problems, up to about half in some populations, and that gene is inherited from both parents in the ordinary way. A negative mitochondrial result and a normal hearing test in a relative do not rule it out, and the nuclear panel is a separate order.

When the Result Can Mislead You

The biggest trap isn't a false positive. It's a negative result from a test that never looked.

• Panel coverage: mitochondrial DNA is routinely left out of standard targeted gene panels and exome tests. An exome test reads the protein-coding parts of your nuclear DNA and skips the mitochondrial loop unless the lab deliberately adds it back. A clean result on a broad genetic panel does not clear you for MT-RNR1 unless the report explicitly says mitochondrial DNA was covered. Some labs recover the sequence from off-target reads, but that is a deliberate analysis choice, not a default.
• Panel scope versus full gene: rapid point-of-care kits and targeted assays look at predetermined positions, usually m.1555A>G and sometimes m.1494C>T. They cannot see anything else in the gene. Full sequencing reads the whole thing.
• How much of your mitochondrial DNA carries it: a variant can sit in only a fraction of your mitochondria. Low fractions are harder for some assays to pick up, and harder to interpret when they are picked up.
• Ancestry and variant frequency: variant frequencies differ substantially between populations, and much of the published work comes from East Asian, European, and specific regional cohorts. What a given result means depends partly on where your maternal line comes from.
• Uncertain significance: an unexpected variant may be reported with no established clinical meaning. It is not a diagnosis and should not change your antibiotic plan on its own.

The Broader Mitochondrial Picture

Beyond the ear, large studies of population DNA have started mapping mitochondrial variation onto other conditions. In a multi-ancestry analysis of roughly 600,000 people, m.1555A>G was linked to higher rates of heart inflammation and heart failure among European women, echoing older clinical reports of heart muscle disease passed down the maternal line. Harmful mitochondrial variants as a group clustered around hormone and metabolic conditions.

Hold that loosely. The evidence behind the hearing story is deep and consistent; the cardiometabolic signal is one large study, in specific subgroups, from a marker whose primary job is elsewhere. It is not a reason to test, and a positive result should not send you looking for heart disease you have no other reason to suspect.